Leukemia Research and Treatment

Research Article

Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Table 1

Patient characteristics.
Characteristics Number (%)
Number of patients160
Median age (range), years 24.6 (0.6–61.8)
Age < 18 years 62 (39)
Gender (male/female)99/61
Lineage type 
 B-ALL134 (84)
 T-ALL 24 (15)
 Biphenotypic leukemia 2 (1)
Cytogenetic subgroup 
 Normal 99 (62)
 t(9;22) 31 (19)
 Other unfavorable abnormalities (−7, +8, 11q23) 15 (9.5)
 Other karyotypic abnormalities 15 (9.5)
Disease status at time of HCT 
 CR1 90 (56)
 CR2 58 (36)
 ≥CR3 12 (8)
Donor Origin 
 Related 51 (32)
 Unrelated 109 (68)
Donor type ( , excluding cord blood) 
 Match 102 (64)
 Mismatch 23 (14)
Graft source  
 Bone marrow 59 (37)
 Mobilized blood 66 (41)
 Cord blood 35 (22)
TBI based conditioning 142 (89)
GVHD prophylaxis 
 Tacrolimus based regimen100 (62%)
 CSP based regimen30 (19%)
 Other30 (19%)